Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Parallel-Group Study to Evaluate the Efficacy and Tolerability of Two Dosing Regimens of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

NCT03811912 is registered in ClinicalTrials.gov with Concert Pharmaceuticals as lead sponsor.

NCT NCT03811912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03811912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Parallel-Group Study to Evaluate the Efficacy and Tolerability of Two Dosing Regimens of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Lead sponsor
Concert Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
March 21, 2019
Completion date
November 21, 2019
Enrollment
57 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

alopecia areata